KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $232.4 million.

  • Sarepta Therapeutics' Cash from Investing Activities rose 28039.98% to $232.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.6 million, marking a year-over-year increase of 111152.3%. This contributed to the annual value of $755.6 million for FY2024, which is 55569.8% up from last year.
  • Sarepta Therapeutics' Cash from Investing Activities amounted to $232.4 million in Q3 2025, which was up 28039.98% from $32.2 million recorded in Q2 2025.
  • Sarepta Therapeutics' Cash from Investing Activities' 5-year high stood at $764.1 million during Q4 2024, with a 5-year trough of -$785.8 million in Q1 2022.
  • Its 5-year average for Cash from Investing Activities is $616947.4, with a median of $12.5 million in 2023.
  • In the last 5 years, Sarepta Therapeutics' Cash from Investing Activities tumbled by 120137.04% in 2023 and then skyrocketed by 165148.9% in 2024.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Cash from Investing Activities stood at -$2.6 million in 2021, then soared by 480.13% to $9.8 million in 2022, then plummeted by 756.98% to -$64.4 million in 2023, then soared by 1287.29% to $764.1 million in 2024, then plummeted by 69.59% to $232.4 million in 2025.
  • Its last three reported values are $232.4 million in Q3 2025, $32.2 million for Q2 2025, and -$291.2 million during Q1 2025.